ABOUT

썸네일

2023

04
Selected as a Super-gap Technology Startup 1000+ (DIPS 1000+) Project from the Ministry of SMEs and Startups
썸네일

2022

09
Selected as a non-clinical development project from National New Drug Development Program by KDDF (Korea Drug Development Fund)
06
Signed MOU with K-MEDI hub for Research Collaboration Agreement
Signed licensing agreement with K-MEDI hub / MFC0101 Licensing-in
A MEDICHEM team is formed
04
Received Series A Institutional Funding
04
Joint research contract for the development of cancer immunotherapy (Seoul National University College of Medicine) / MFC0101

Joint CSO contract with ShiftBio for the development of exosome-based cancer immunotherapy
03
Signed intellectual property consulting agreement contract with United One Law Group LLC.
02
Joint research contract with Korea University for the discovery of cancer stem cell-based therapy
썸네일

2021

12
Headquarter/Research center relocated to 7F WOOJUNGBIO Cluster, 593-8 Dongtangiheung-ro, Hwaseong-si, Gyeonggi-do, 18469, Republic of Korea
08
Joint research contract for the development of Anti-viral treatment (Chungbuk National University College of Medicine) / MFC0102
03
Joint research contract with Korea University for the development of NASH treatment / MFC0102
썸네일

2020

09
Joint research contract with Korea University for the discovery of cancer stem cell-based therapy
08
Joint research contract for the development of Anti-viral treatment (Chungbuk National University College of Medicine) / MFC0102
07
Joint research contract with K-MEDI hub for the development of 'First-in-Class drug' (Structural Biology) / MFC0301
04
Appointed as military service designated company from Military Manpower Administration
03
Joint research contract with K-MEDI hub for the development of 'First-in-Class drug' (Molecular design) / MFC0301
썸네일

2019

09
Joint research contract with K-MEDI hub for the development of 'First-in-Class drug' (Structural Biology) / MFC0101
Joint research contract with K-MEDI hub for the development of 'First-in-Class drug' (Lead Optimization) / MFC0101
08
Joint research contract with Korea University for the discovery of cancer stem cell-based therapy
07
Granted One-Stop support project with K-MEDI hub
06
Received Pre-Series A Institutional Funding
02
Certified as venture company from KOITA (#20190100921)
썸네일

2018

07
Certified as Research Institute in MEDIFIC
02
Founded at Korea University, Seoul, South Korea